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Introduction {#sec1}
============

Intracellular signaling networks are complex machineries that reliably receive and process extracellular information to adjust the physiological state of cells to environmental changes. The signaling networks are formed by the interplay of hundreds of proteins and second messengers (ions, lipids, triphosphates, etc.) featuring an extensively branched and feedback-based architecture ([@bib17], [@bib25], [@bib28]). Recently, it was established that signaling networks have a remarkable ability to encode the identity and quantity of a given stimulus by temporal patterns and/or dynamics of individual signaling components within the network architecture ([@bib17], [@bib19], [@bib30], [@bib38]). These signaling network characteristics result in precise control over cellular responses and the ability to adapt to various perturbations. The prediction of the latter is of great interest for basic and translational research. A better understanding of signaling network operation will allow manipulating key parameters with higher precision and therefore facilitate the development of new pharmacological strategies. To understand how cellular signaling networks integrate information from the extracellular environment, how they evoke specific cellular responses and, most importantly, how normal signaling is rewired under the course of a disease, a method is needed that allows comprehensive system-level analysis of multiple signaling pathway dynamics under identical conditions. Such a toolbox should be able to detect second messengers as well as key protein activities of the network with high temporal resolution, and also clarify the interplay between signaling events and phenotypic changes.

Current high-throughput approaches to measure activation of a signaling network at a single-cell level include flow and mass cytometry, microfluidics, single-cell western blot, and fluorescence lifetime imaging microscopy on cell arrays (CA-FLIM) ([@bib4], [@bib9], [@bib14], [@bib15], [@bib16]). Although these single-cell methods provide advantages such as multiplexed quantification, they all suffer from several drawbacks. Most of the methods are based on endpoint measurement of post-translational modifications (PTMs) resulting in limited information on dynamic changes. The second challenge is their dependence on highly specific antibodies because cross-reactivity induces misleading signals in complex biological backgrounds, for which it is difficult to correct ([@bib34]). The third challenge is to employ a single phosphorylation state or another PTM as an approximation for protein activity, which is not necessarily the case ([@bib10], [@bib22]). Finally, flow cytometry only works with a suspension of cells. Placing inherently adherent cells in a non-natural, suspension environment likely alters the activity of a signaling network and makes it difficult to relate signaling events to a phenotypic difference.

In this study, we describe a Förster resonance energy transfer (FRET)-based multi-parameter imaging platform (FMIP) that allows monitoring of the activity of multiple signaling pathways in adherent single live cells with high temporal resolution. The FMIP exploits publicly available FRET biosensors, uses conventional microscopes and, by taking advantage of cell microarrays ([@bib43]), is able to image up to 384 FRET sensors in a single experiment. To illustrate the potential of the platform, we used 40 FRET biosensors in a single experiment and we profiled a cancer-relevant signaling network by monitoring: (1) the perturbation of epidermal growth factor receptor (EGFR) signaling caused by the activating mutation L858R and the resistance mutation T790M of EGFR, (2) the effects of an MEK inhibitor on EGFR network activity; and (3) the crosstalk of the EGFR and insulin-like growth factor-1 receptor (IGF-1R) signaling networks.

Results {#sec2}
=======

Design of a FRET-Based Multi-parameter Imaging Platform {#sec2.1}
-------------------------------------------------------

FRET biosensors are used to measure the conformational change of proteins reflecting protein-protein interaction, post-translational modification, concentration of second messengers and, most importantly, protein activities, not merely abundance ([@bib26]). As FRET biosensors measure protein activity at the single-live-cell level in real-time, they offer information on signaling network dynamics. Importantly, FRET biosensors can be successfully used in high-throughput experiments ([@bib2]). Thus, we reasoned that FRET biosensors are an ideal tool for monitoring multiple signaling events simultaneously in a high-throughput manner.

By combining time-resolved single-live-cell imaging with advances in cell microarrays ([@bib29], [@bib43]) and FRET biosensor technologies, we developed an FMIP to analyze the dynamics of various signaling pathways in real-time. The FMIP employs Lab-Tek chambers printed with 384 spots (200 μm diameter) in a grid-like manner. Each spot contains a plasmid encoding one of 40 different FRET biosensors ([Table S1](#mmc1){ref-type="supplementary-material"}), in replicates ([Figure 1](#fig1){ref-type="fig"}A). Adherent mammalian cells are seeded on Lab-Tek chambers pre-printed with FRET biosensors and incubated for 48--72 hr. Each individual spot out of 139 contained cells expressing one of the 40 different FRET biosensors. These are imaged every 3 min with an automated microscope ([Figure 1](#fig1){ref-type="fig"}A). Subsequently, image segmentation and intensity measurements are carried out automatically by an in-house developed Fiji macro ([Figure S1](#mmc1){ref-type="supplementary-material"}). The method allows time-resolved monitoring of signaling network dynamics at the single-cell level by taking ratiometric images of the 139 spots within 3 min. Less spots would permit faster data acquisition for each spot. Compared with single-FRET sensor imaging in isolated dishes, FMIP facilitates reproducibility since all cells are placed in a single dish under identical conditions. In comparison with multiplexed expression of FRET biosensors, the FMIP is also less affected by perturbations of the introduced FRET biosensors ([@bib23]) as each transfected cell expresses only one construct.

Using a slightly modified reverse-transfection protocol described previously ([@bib29]) ([Figure 1](#fig1){ref-type="fig"}A), we successfully transfected different cell lines such as HeLa, H838, C2BBe1, and MIN6 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A), demonstrating that the FMIP method is applicable to various cultured cell lines. The transfection rates were sufficient to monitor an average of 27--150 cells (depending on the cell line and FRET biosensor) in a single experiment enabling single-cell variation analysis.

To assess whether cells within one spot would become contaminated with plasmids from neighboring spots or cross-contaminated due to cell migration, we printed two plasmids encoding enhanced CFP (ECFP) and EGFP in an alternating pattern. The fluorescence images showed no significant ECFP expression on EGFP-transfected spots and, vice versa, demonstrating clear separation of transfected cells to the respective spots ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).

Next, we determined if the FMIP platform could reliably report time-dependent changes in the well-studied epidermal growth factor (EGF) signaling network ([@bib6], [@bib21], [@bib39]). As expected, EGF triggered activation of Ras-ERK and PDK1-Akt-S6K pathways in HeLa cells ([Figures 1](#fig1){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B) as well as in H838 cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) in a concentration-dependent manner. We used the resulting profile of normalized FRET ratio values as a fingerprint of dynamic responses to hierarchically cluster the time courses of protein activity after EGF addition, which induced distinct kinetics of protein activation. The protein activity dynamics clearly segregated into three clusters: strong, middle, and weak ([Figure 1](#fig1){ref-type="fig"}C). The low average coefficient of variation (CV) across replicate experiments over time (7.3%) confirmed the very high data reproducibility. However, not unexpected, we observed much higher variability (depending on the FRET biosensor, CV \< 30%) between individual cells within the same experiment ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B) for a responding FRET sensor. The experiment reproduced a broad range of observations from previously published studies ([@bib12], [@bib39]), demonstrating its ability to examine the dynamics of the signaling network by monitoring activities of 40 signaling events in parallel.

To test whether biosensor overexpression perturbed the signaling network under observation, we evaluated the effect of FRET biosensor expression in response to EGF. We therefore recorded the change of the FRET biosensor expression level in untreated HeLa cells over time ([Figure S6](#mmc1){ref-type="supplementary-material"}). Although in most cases, the intensity of CFP and the FRET channel emission was increased, the FRET ratio was much more stable demonstrating the advantage of using ratiometric FRET biosensors in general as they provide an internal control for the expression level when the ratio of the FRET channel over the CFP channel is used ([@bib37]). Moreover, we observed a very weak or no correlation, except for a Ras FRET biosensor (r = −0.33, p \< 0.0001), between the maximal normalized FRET ratio value and the expression level of the FRET biosensors ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Overall, the data suggest that the assay provides a robust and reproducible readout of signaling network activity at the single-cell level.

Monitoring Perturbations of EGFR Signaling Network Activity {#sec2.2}
-----------------------------------------------------------

Functional mutations in the cellular genome causing aberrant signaling network activity have been implicated in the progression of various diseases including cancer. Therapies that counteract the downstream effects of the mutation may reverse the course of the disease. To evaluate FMIP in such applications, the activity of the EGF signaling network was pharmacologically perturbed in HeLa cells using a clinically relevant MEK inhibitor (selumetinib or AZD6244) ([@bib3]). As predicted, addition of AZD6244 completely abrogated the activity of ERK and RSK ([Figures 2](#fig2){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}A). In contrast, the activity of Ras, Cdc42, EGFR and FAK was not affected ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Surprisingly, AZD6244 exhibited a strong effect on PKA activity ([Figure S7](#mmc1){ref-type="supplementary-material"}A) and modest effects on Akt, PDK1, S6K, JNK, and Src activities ([Figure S7](#mmc1){ref-type="supplementary-material"}B). The results suggest two scenarios: (1) potential off-target effects of the inhibitor and/or (2) an unpredicted topology of the EGF signaling network. These observations demonstrate that FMIP is a powerful technique that may become highly relevant in the drug discovery process exploring drug targets and off-targets, as well as mechanisms of action across multiple disease settings.

To analyze how pathophysiologically relevant EGFR mutations perturb the signaling network, we profiled EGF signaling activity in lung cancer metastases-derived H838 cells expressing the wild-type EGFR and compared the results to H838 cells harboring the exogenously expressed EGFR that carries the activating mutation L858R and the resistance mutation T790M (H838-EGFRmut). We observed a strong decrease in activity of kinases such as Src, Abl, PKA, and RSK upon stimulation with EGF and modest reduction of Akt, ERK, S6K, PDK1, and JNK activities in H838-EGFRmut cells compared with H838 wild-type cells ([Figures 2](#fig2){ref-type="fig"}B and [S8](#mmc1){ref-type="supplementary-material"}). To compare global response patterns between cells expressing EGFRmut and wild-type EGFR, we subjected the obtained EGF signaling data from HeLa (EGFRwt), H838 (EGFRwt), H838 exogenously expressing EGFRmut, and H1975 endogenously expressing EGFRmut cells to principal component analysis (PCA) ([Figure 2](#fig2){ref-type="fig"}C). The latter indicates that the global EGF signaling dynamics in H838-EGFRmut and H1975 were clustered together indicating the strong similarity of endogenously and exogenously expressing EGFRmut cells. Interestingly, we observed strong differences between global responses in HeLa and H838 cells suggesting cell line-dependent differences ([Figure 2](#fig2){ref-type="fig"}C). Overall, the FRET biosensors in H838-EGFRmut cells responded to EGF with a much altered dynamic pattern in comparison with wild-type H838, providing insight into the changes of this signaling network in response to disease-causing and network-perturbing mutations. Such analysis may form the basis for the unbiased profiling of the clinically observed mutations for their ability to perturb various signaling networks as well as to quantitatively assess the degree of such perturbation, providing information relevant for disease progression, prognosis, design of therapeutic treatment, and drug discovery.

Monitoring the Crosstalk of the EGFR and IGF-1R Signaling Networks {#sec2.3}
------------------------------------------------------------------

Despite a detailed characterization of signal transduction induced by a single growth factor, it is not well understood how cells integrate and process information of multiple stimuli ([@bib7], [@bib42]), which is a physiologically common scenario. We therefore used FMIP to investigate unique and redundant features of EGFR and IGF-1R signaling networks. By using the FMIP platform, we monitored the signaling network in a time-dependent fashion after stimulation with EGF only, IGF-1 only, or after co-stimulation using varying concentrations of growth factors. At the single-cell level, we found that the FRET biosensor response was highly variable across all conditions ([Figure S9](#mmc1){ref-type="supplementary-material"}). Notably, we identified pulsatile activity of ERK (12.5 ng/mL EGF) and Src (100 ng/mL EGF) in some cells that would have been very difficult to obtain using population or/and endpoint assays ([Figure S9](#mmc1){ref-type="supplementary-material"}).

To study signaling network activity at the single-cell level, we combined all single-cell trajectories for each FRET biosensor from across all treatments, on average 2,000 cells per biosensor, and subjected the data to K-means clustering to estimate six representative dynamic patterns ([Figure S10](#mmc1){ref-type="supplementary-material"}). We used the proportion of cells in these clusters as unique signatures of dynamic activity ([Figures 3](#fig3){ref-type="fig"}A--3E and [S10](#mmc1){ref-type="supplementary-material"}). In agreement with previous work ([@bib39]), we observed stronger activation of the PDK1/Akt/S6K pathway by IGF-1 than by EGF ([Figures 3](#fig3){ref-type="fig"}A and 3E). In contrast, EGF is a much stronger activator of the Ras/ERK/RSK and Src/FAK pathways. Notably, co-stimulation of the cells with EGF and IGF-1 showed concentration-dependent features that are characteristic signatures of "EGF only" and "IGF-1 only" treatments ([Figures 3](#fig3){ref-type="fig"}A--3E). Importantly, the response of the RhoA 2G biosensor suggested decreased activity of RhoA upon co-stimulation, correlating with the findings obtained in another cell type ([@bib27]) ([Figure S11](#mmc1){ref-type="supplementary-material"}). Surprisingly, we also observed decreased response of the PIP~3~ and Abl FRET biosensors upon co-treatment with EGF and IGF-1, suggesting crosstalk between EGF and IGF-1 signaling. We further subjected the data to PCA. We found that EGF, IGF-1, and combined treatments were clearly clustered ([Figure 3](#fig3){ref-type="fig"}F). The PCA indicated that "IGF-1 only" treatment was most separated from "EGF only" stimulation, whereas combined treatments moved the cluster in between "EGF only" and "IGF-1 only." Strikingly, depending on the ratio of the growth factors the cluster is shifted toward the direction of the growth factor with the higher concentration ([Figure 3](#fig3){ref-type="fig"}F). However, the shift in the PCA space is not proportional to the ratio of the growth factors suggesting interaction (synergy and/or antagonism) between EGF and IGF-1. Overall these observations indicate strong crosstalk and a potential similarity of the signaling networks. In addition, the FMIP method coupled to a PCA analysis illustrated an ability of signaling networks to be tuned with remarkable precision and achieve a potentially unlimited number of different states depending on the relative contribution of the activating stimuli.

Finally, to obtain a mechanistic insight into the integration of EGF and IGF-1 signaling, we focused on individual signaling nodes. To visualize the crosstalk between EGF and IGF-1, we computed a synergy score for each responding FRET biosensor to form a composite "synergy map" under various concentrations ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S12](#mmc1){ref-type="supplementary-material"}). We hypothesized that if the action of EGF and IGF-1 were independent, we would observe additive effects (Ss = 0, additivity), whereas interactions due to receptor cross-reactivity, downstream signal amplification/inhibition, or autocrine signaling would cause non-additivity (Ss \> 0, synergism; Ss \< 0, antagonism) ([Figures 4](#fig4){ref-type="fig"}A and 4B). Surprisingly the synergy map was dependent on the concentration of growth factors, which explains the non-proportional shift in the PCA space ([Figure 4](#fig4){ref-type="fig"}B). For example, the highest concentration of both EGF and IGF-1 strongly activate S6K although with different dynamics, but the combined action of the two is lower than that expected for their additive effect (antagonism) ([Figure 4](#fig4){ref-type="fig"}C). However, the decrease of either EGF or IGF-1 concentration induces the strongly or no synergistic effect in the late phase of S6K activation, respectively. Surprisingly, the proportional decrease of EGF and IGF-1 concentrations led to a slight antagonism in S6K activation. The comparison of the average synergy score reveals that under the highest concentrations of EGF and IGF-1 Ss is negative (Ss = −0.24), suggesting the saturation of the shared molecular signals of these growth factors ([Figure 4](#fig4){ref-type="fig"}B). Notably, decreased concentration of one of the growth factors or both of them in the co-treatment elevated the average synergy score (100 ng/mL EGF + 6.25 ng/mL IGF, Ss = 0.32; 6.25 ng/ml EGF + 100 ng/mL IGF, Ss = 0.27; 12.5 ng/mL EGF + 12.5 ng/mL IGF, Ss = 0.18), indicating strong synergy between EGF and IGF-1. The hierarchical clustering also indicates that the signaling activities can be clearly segregated into at least two groups by synergy properties: synergistic and antagonistic responses ([Figure 4](#fig4){ref-type="fig"}B). Taken together, these data show concentration-dependent EGF/IGF-1 crosstalk and support the concept that dynamically encoded information ([@bib17], [@bib30]) is a potential mechanism by which information from combined stimuli integrate to regulate signal-specific cellular processes. Thus, the FMIP provides a unique technique enabling the investigation of signaling network crosstalk at a systems level in an unbiased way.

Discussion {#sec3}
==========

By using microarray technology, we developed a powerful method to image FRET biosensors for monitoring enzyme activities in a high-throughput manner. The resulting platform (FMIP) is useful for simultaneously measuring a variety of intracellular signaling responses to a given set of stimuli at a single-live-cell level. We demonstrate the ability of this platform to profile perturbations caused by functional mutations of EGFR and a clinically important MEK inhibitor (AZD6244, selumetinib). We also show that this platform is able to partially resolve the signaling crosstalk between EGFR and IGF-1R.

As a way to demonstrate the power of the technique, we show that the MEK inhibitor AZD6244 is able to dramatically inhibit the activity of ERK, RSK, and, surprisingly, PKA following stimulation by EGF in HeLa cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A and [S14](#mmc1){ref-type="supplementary-material"}). Moreover, comparing the synergy score pattern between PKA and RSK across various concentrations of EGF and IGF-1 indicated that high synergy in RSK correlates with high synergy in PKA responses in the presence of EGF ([Figure 4](#fig4){ref-type="fig"}B). We also observed that the activity of PKA strongly correlated with the activity of RSK and ERK ([Figure S13](#mmc1){ref-type="supplementary-material"}) in the presence of EGF. Overall, the data suggest that the activity of RSK and PKA is co-regulated or that one of the proteins positively regulates the other. In support of this hypothesis, it was shown previously that RSK can directly bind to PKA and regulate its activity ([@bib13]). Also, this study on B82L cells reported that active RSK attenuated the phosphorylation of the Bcl-xL/Bcl-2-associated death promoter on Ser-115 by PKA, indicating a negative regulation of PKA activity by active RSK. In contrast, our data indicate a more complex interplay between RSK and PKA. In our experiments, we observed activation of PKA by various concentrations of EGF ([Figure S3](#mmc1){ref-type="supplementary-material"}), but in the study mentioned above there is no difference between EGF-treated and -untreated cells. The difference was observed only upon additional treatment with 8-pCPT-cAMP (the slowly hydrolyzing analog of cAMP) giving rise to the possibility that the experimental setup was less sensitive. We cannot rule out effects due to differences in the signaling network architecture and/or in the level of gene expression between HeLa and B82L cells, but we suspect that monitoring PKA activity over 5 hr with the AKAR3EV FRET biosensor more accurately reflects the dynamic activity of PKA under quasi-physiological conditions.

A long-standing question in the field of cellular signaling is how signaling networks integrate and process information from multiple extracellular cues. It was recently suggested that interactions between two stimuli are highly combinatorial and might be segregated into at least ten interaction modes governing gene expression ([@bib8]). By using similar synergy score metrics to those described previously ([@bib20], [@bib25]), we show that the interaction modes (synergy, additivity, or antagonism) between EGF and IGF-1 are highly variable among downstream signaling molecules ([Figure 4](#fig4){ref-type="fig"}B). Moreover, we demonstrate that the interaction mode is concentration dependent ([Figures 4](#fig4){ref-type="fig"}B and 4C). Thus, it will be of great interest to determine how information from other physiological stimuli including growth factors such as hepatocyte, fibroblast, or nerve growth factors is integrated by signaling networks and most importantly to understand how this combinatorial code is interpreted (or decoded) on the level of gene expression. We believe that extensive gene expression studies in combination with signaling data provided by our imaging platform will help to answer those questions in the near future.

Our FMIP platform currently uses only FRET biosensors but could be extended with any fluorescence-based biosensor (such as translocation probes) ([@bib31]) or in combination with small interfering RNAs. The platform could also be adapted for hard-to-transfect primary cells by implementation of lentivirus-infected cell microarrays ([@bib1]). Importantly, the FMIP could be combined with a perfusion system and optogenetics ([@bib38]) or caged molecules ([@bib24]) to manipulate the extracellular environment and activity of isolated molecules in a highly controlled manner, respectively. As the effectiveness of FMIP is strongly dependent on the performance of each sensor and current settings allow monitoring of up to 384 FRET biosensors in a single experiment, we believe that future advances in biosensor development to cover additional parameters and to provide improved dynamic range, sensitivity, and selectivity of existing biosensors will further improve the performance of the platform in the near future.

We anticipate that this powerful platform will be useful for understanding signal transduction mechanisms and will help to describe signaling networks in a more systematic way. We expect applications of the FMIP to study drug action, to determine side effects of drugs on vital cellular functions, and to understand cellular mechanisms of therapeutic resistance to drug treatments after long-term exposure.

Significance {#sec4}
============

**To better understand complex intracellular signaling networks, technologies that enable simultaneous measurement of protein activities and second messenger concentrations are essential for basic and clinical research. FRET biosensors are able to visualize the dynamic *activity* of proteins, not merely abundance, and concentrations of second messengers with high temporal resolution in a single live cell. However, so far the high-content capability was limited to a few FRET biosensors. Here, by using cell microarray technology in combination with FRET biosensors and live-cell imaging, we developed a high-content imaging platform that allows visualizing of hundreds of FRET biosensors in a single experiment. As a proof of principle, by employing 40 FRET biosensors, we have demonstrated the capability of this platform to monitor perturbations in the EGF signaling network caused by overexpression of constitutively active EGFR and by a clinically relevant MEK inhibitor. We also show that our platform is able to resolve a crosstalk between growth factors. Our technique provides the potential to study signaling networks in disease and hence improve drug discovery, to identify mechanism of action and side effects of therapeutic candidates, as well as to investigate principle signal transduction mechanisms.**

Experimental Procedures {#sec5}
=======================

Cells and Reagents {#sec5.1}
------------------

HeLa Kyoto cells were a kind gift of R. Pepperkok (European Molecular Biology Laboratory, Germany). HeLa Kyoto cells were maintained in low glucose DMEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS) and with 100 μg/mL of Primocin (InvivoGen). H838 cells were maintained in high glucose DMEM (Life Technologies) supplemented with 10% FBS and with 100 μg/mL of Primocin (InvivoGen). Starvation media for HeLa Kyoto cells contained low glucose DMEM (Life Technologies) and 100 μg/mL of Primocin (InvivoGen). Starvation of H838 cells and H838 cells expressing EGFR with both activating L858R and resistant T790M mutations was performed in high glucose DMEM (Lonza) supplemented with 1 mg/mL of BSA (Sigma), 2 mM L-glutamine (Invitrogen), 100 units/mL penicillin, and 100 g/mL streptomycin (Pen-Strep, Invitrogen). AZD6244 was purchased from Selleck Chemicals (selumetinib). EGF and IGF-1 were obtained from Sigma.

Establishment of a Stable Cell Line {#sec5.2}
-----------------------------------

cDNA of the human EGFR harboring the L858R and T790M mutation was purified from H1975 cells (ATCC) by extraction of mRNA with the RNeasy Kit (QIAGEN) and reverse transcription (Agilent). The cDNA was used as template for PCR with gene-specific primers containing XhoI and PacI restriction sites and subcloned into pMOWS vector containing puromycin resistance ([@bib32]). The plasmid was transiently transfected in phoenix-ampho packaging cells ([@bib35]) by calcium phosphate precipitation. After 16 hr incubation, the retroviral particles were harvested from the supernatant, filtered with a 0.45 μm filter (Millipore), and used for transduction of the H838 cell line (ATCC). H838 cells were centrifuged in a 6-well plate with 1 mL viral supernatant, containing 8 mg/mL polybrene, for 3 hr at 340 × *g*. The cells were selected the following day using 1.5 μg/mL puromycin (InvivoGen, catalog no. ant-pr-1). H838-EGFR L858R/T790M cells were cultivated in DMEM medium containing 10% fetal calf serum, 1% penicillin/streptomycin, and 1.5 μg/mL puromycin.

Contact Printing {#sec5.3}
----------------

The reverse-transection approach developed in this work is a modified version of previously described protocols ([@bib11], [@bib29]) to achieve better transfection efficiency. In brief, plasmids for reverse transfection were isolated from *Escherichia coli* using a maxi QIAfilter Plasmid Maxi Kit and diluted to concentration of 1 mg/mL. To prepare the transfection mixture, 9 μL of a 0.4 M sucrose solution in DMEM, 9 μL of DNA and 33 μL of Lipofectamine 2000 were mixed in a 96-well plate. After 20 min incubation at room temperature, 21.75 μL of solution of 0.29% gelatin in water was added to the mixture, and 24 μL of the transfection cocktail was distributed in 384-well plates. Subsequently, a plate was centrifuged briefly up to 54 × *g* at room temperature to straighten the surface of the samples and placed immediately in the contact printer. Before printing, Lab-Tek dishes were washed with 70% ethanol to increase the hydrophobicity of the Lab-Tek surface and, accordingly, to improve the shape of the spots. One-well Lab-Tek dishes were printed with a "ChipWriter" contact printer equipped with solid pins. Using PTS 600 pins, the diameter of printed spots was about 400 μm and the spot-to-spot distance was 1.125 μm. Printed 1-well Lab-Tek dishes were stored at room temperature in a gel-drying box in the presence of drying pearls.

Imaging {#sec5.4}
-------

Cells (650,000) were seeded onto a printed glass coverslip 1-well Lab-Tek chamber. After maintaining cells in an incubator for 24--48 hr, the media were changed to starvation media (see above) at least 12--17 hr prior to imaging. To assist cellular segmentation cell lines were incubated with 7.5 nM DRAQ5 (Cell Signaling Technology). During imaging, cells were maintained in imaging medium (minimum essential medium supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin, and 30 mM of HEPES) at 37°C without CO~2~. Time-lapse imaging was performed on an Olympus IX83 microscope equipped with a Hamamatsu ImagEM CCD camera and an environmental chamber using 20× 0.70 numerical aperture (NA) or 10× 0.40 NA and 436/20 excitation filter, a CFP/yellow fluorescent protein (YFP) dual-band beam splitter (51017bs; Chroma), and two emission filters (470/30 for CFP and 535/50 for YFP) that were controlled by a filter wheel. The images were captured with xCELLence software at 3 min interval.

Imaging Data Analysis {#sec5.5}
---------------------

Primarily, the binary mask for the nucleus was defined using a DRAQ5 marker and all channels were combined in a single file by the in-house developed ImageJ Macro ([@bib33]). Subsequently, images were analyzed with ImageJ Macro FluoQ as depicted in [Figure S1](#mmc1){ref-type="supplementary-material"} and as described previously. In brief, the mean of the thresholded background calculated with a histogram-based "Triangle" algorithm is subtracted from each pixel. Images were then smoothed with a median filter (radius size = 2) and transformed to a 32-bit float. To segment cells, a binary mask was created by Huang\'s fuzzy thresholding method. The signal intensity that was equal or close to intensity of the background was set as NaN value due to Huang\'s fuzzy thresholding. The CFP intensity of cells ranged from 700 to 8,000 a.u. depending on the FRET biosensor. This image analysis pipeline automatically excludes low-expressing cells and avoids erroneous FRET ratios. The FluoQ macro identified cell nuclei from the images of a binary mask. The cell outlines were then identified using the watershed algorithm. Finally, the particle analyzer plug-in was used to define regions of interest (ROIs). To simplify and fasten the image analysis pipeline that is capable of analyzing 13,900 images from a single experiment in a reasonable time window we averaged the intensity of FRET, CFP, and FRET ratios over each ROI. Taken into account that many signaling pathways are compartmentalized, the spatial variation of the sampled signals and significant fluctuations might be averaged out due to averaging over each ROI. In all experiments, the FRET ratio from before stimulation was averaged and used for normalization. FluoQ provided the mean pixel intensity of each ROI over time, saved all measured data, and calculated parameters in a text file format (EXPNAME.txt).

Statistical Analysis {#sec5.6}
--------------------

To perform data analysis, a text file was loaded into the program R ([@bib36]). The R package "ggplot2" ([@bib41]) was used to visualize the data. Clustering was performed using the heatmap.2 function of the R package "gplots" ([@bib40]). We observed that the intensity of CFP and FRET channels is increasing over time most probably due to a constant increase in FRET biosensor expression, as depicted in [Figure S6](#mmc1){ref-type="supplementary-material"}A, taking into account that we performed the imaging over 5 hr. Although the intensity of CFP and FRET channels is increased the FRET ratio is much more stable ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Therefore, to minimize the impact of FRET sensor expression and/or photobleaching, the single-cell time courses were normalized to the FRET ratio mean of cells treated with a vehicle (imaging medium) at each time point and to the average of data points prior to the stimulation in [Figures 1](#fig1){ref-type="fig"}B, 1C, [3](#fig3){ref-type="fig"}A--3E, [4](#fig4){ref-type="fig"}B, 4C, [S3](#mmc1){ref-type="supplementary-material"}A, S3B, [S9](#mmc1){ref-type="supplementary-material"}, [S10](#mmc1){ref-type="supplementary-material"}, and [S11--S13](#mmc1){ref-type="supplementary-material"}. If not stated otherwise, the overall FRET ratio for a reporter is represented as a normalized FRET ratio mean of all individual cells from identical conditions ± SEM, where the SEM is calculated from all cells in all experiments under identical conditions. In [Figures 1](#fig1){ref-type="fig"}B, 1C, and [S4](#mmc1){ref-type="supplementary-material"}B, the maximum observed FRET ratio value of each biosensor was additionally used for normalization.

The statistical significance (p value) for Kendall\'s tau correlating coefficients was determined using the program R. The exact p value is computed if there are less than 50 paired samples containing finite values and there are no ties. Otherwise, the test statistic is the estimate scaled to zero mean and unit variance, and is approximately normally distributed. In [Figure 2](#fig2){ref-type="fig"}C, PCA was performed on a 340 × 14 matrix, with 85 time points, and 4 cell lines each with 14 FRET biosensors. In [Figure 3](#fig3){ref-type="fig"}F, PCA was performed on a 546 × 17 matrix, with 546 time points, growth factors, and dose each with 17 FRET biosensors. We used the prcomp function with centering and scaling of the program R to perform PCA analysis and the R package "ggplot2" for visualization.

To estimate the additive effects of a combined EGF and IGF treatment, we first normalized every single-cell time-trace by dividing each time point with the average of data points prior to the stimulation and with the mean value of untreated cells followed by a subtraction of 1. Then we computed the area under the curve for each individual cell. The data were analyzed for normality using the Shapiro-Wilk test and the quantile-quantile plot. We then averaged the area under the curve for the corresponding sensor and stimulus and computed the SEM to estimate the error for calculated additive response. We calculated the expected response by simple addition of the mean of the area under the curve of "EGF only" and "IGF-1 only" treatments. To estimate the combined error, we performed a simple error propagation of the individual SEs of the mean using a variance formula ([@bib18]). Student\'s two-sample t test was used to determine whether there was a statistically significant difference between the means of experimental and the expected (calculated) additivity. The p values obtained were corrected for multiple testing ([@bib5]). The synergy score were calculated as the difference between the means of experimental and expected (calculated) additivity. In [Figure 4](#fig4){ref-type="fig"}B, the synergy scores with all insignificant difference (p ≥0.05) are in white ([Figure S12](#mmc1){ref-type="supplementary-material"}). To simplify visualization, the synergy score was scaled to the maximum synergy score observed for a FRET biosensor, giving a value that ranges from −1 (antagonism) to +1 (synergy).
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![Design and Characterization of the FRET-Based Multi-Parameter Imaging Platform\
(A) Method workflow.\
(B) Representative FRET ratio traces in HeLa cells expressing sensors for monitoring Ras/ERK/RSK (left) and PDK1/Akt/S6K (right) pathways. Cells were stimulated with EGF (100 ng/mL) at time 0. Data represent mean ± SEM of four independent experiments. The number of cells analyzed is given in parentheses.\
(C) Hierarchical clustering of the EGF (100 ng/mL) response amplitude over time. Clusters of responses are color-coded: strong (red), middle (blue), and weak (green). For each FRET biosensor the mean of four independent experiments is represented.](gr1){#fig1}

![Monitoring Perturbations of the EGF Signaling Network\
(A) Pharmacological perturbation of EGF signaling network activity by the MEK inhibitor AZD6244. HeLa cells were stimulated with EGF (100 ng/mL) at time 0 and treated with DMSO or MEK inhibitor (5 μM) after 69 min. Data represent mean ± SEM of two (DMSO) or three (MEK inh.) independent experiments. Representative cases are shown.\
(B) Perturbation of EGF signaling by expression of constitutively active EGFR. H838wt or H838-EGFRmut cells exogenously expressing the EGFR that carries activating L858R and resistant T790M mutations were stimulated with 50 ng/mL of EGF at time 0. Representative cases are shown. Data represent mean ± SEM (n = 3).\
(C) Principal component analysis of the average EGF response in different cell lines. Each dot represents a single time point while the ovals indicate 70% of time points of the same treatment. Cells were treated with 50 ng/mL EGF.](gr2){#fig2}

![Crosstalk of the EGF and IGF-1 Signaling Networks\
(A--E) Distribution of representative FRET biosensors time series in response to various stimuli. HeLa cells were treated with 100 ng/mL IGF-1 (A), 6.25 ng/mL EGF + 100 ng/mL IGF-1 (B), 100 ng/mL EGF + 100 ng/mL IGF-1 (C), 100 ng/mL EGF + 6.25 ng/mL IGF-1 (D), and 100 ng/mL EGF (E). n \> 1,296 cells.\
(F) Principal component analysis of the average response of the growth factor. Each dot represents a single time point while the ovals indicate 80% of time points of the same treatment.](gr3){#fig3}

![Crosstalk of the EGF and IGF-1 Signaling Networks\
(A) Presentation of the synergy score.\
(B) Synergy map which reflects antagonism, additivity, and synergy due to GFs crosstalk. HeLa cells were stimulated with 100 ng/mL EGF, 12.5 ng/mL EGF, 6.25 ng/mL EGF, 100 ng/mL IGF-1, 12.5 ng/mL IGF-1, and 6.25 ng/mL IGF-1 alone and their combination. The matrix was hierarchically clustered with the Euclidean metric and the Ward's linkage. All insignificant values (p ≥ 0.05) are in white.\
(C) Examples of two classes of signaling molecules separated by concentration-dependent synergy properties: synergistic (PKA and S6K) and antagonistic, Abl. Rectangles depict the synergy scores from (B). Data represent mean ± SEM.](gr4){#fig4}
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